Complementary and Alternative Medicine (CAM) for Fibromyalgia

Not Applicable

Completed

• Conditions: Fibromyalgia

• Registration Number: NCT02053090
• Lead Sponsor: Oregon Health and Science University

Brief Summary

This study is an acceptability and feasibility study of two adjunctive interventions: group education with stretching; and group acupuncture. The study population will be women with primary fibromyalgia who have not previously used acupuncture in the last 3 months. Both interventions will be 10 weeks in length and will be conducted at the Oregon Health \& Science University. The primary hypothesis is that both arms will be acceptable and feasible in the study population.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2014-01-30
• Study First Submitted QC: 2014-01-30
• Study First Posted: 2014-02-03
• Study Start: 2014-08
• Primary Completion: 2015-07
• Study Completion: 2015-07
• Status Verified: 2015-09
• Last Update Submitted: 2015-09-22
• Last Update Posted: 2015-09-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 431

Inclusion Criteria

1. Having met American College of Rheumatology (1990) criteria for the diagnosis of fibromyalgia
2. Having a primary Traditional Chinese Medicine (TCM) diagnosis of either Liver Qi Stagnation, Qi and Blood Stagnation, or Qi and Blood Deficiency
3. Female gender
4. Reported average pain of 5 or higher over last week on a scale of 0 to 10 with ten indicating higher pain.
5. Willingness to limit the introduction or change of any medications or treatment modalities for control of fibromyalgia symptoms during the study
6. No TCM in last 3 months (including acupuncture, Chinese herbs or herbal tea pills, tuina (Chinese massage), shiatsu (Japanese massage), qigong and Oriental food therapy)
7. Ability to travel to the intervention and testing sites up to two times weekly
8. Being over 18 and under 75 years of age, and
9. Capability of giving informed consent.

Exclusion Criteria

1. Presence of a known coagulation abnormality, thrombocytopenia, or bleeding diathesis that may preclude the safe use of acupuncture;
2. Individuals with celiac disease
3. A score greater than 29 on the Beck Depression Inventory
4. Presence of concurrent autoimmune disease such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, that causes pain and could potentially confound the analysis;
5. Routine daily use of narcotic analgesics or history of substance abuse;
6. Concurrent participation in other therapeutic trials;
7. Pregnant and nursing mothers (verification of pregnancy status will be determined via a urine test);
8. Severe psychiatric illnesses (current schizophrenia, major depression with suicidal ideation, substance abuse within two years);
9. Are undergoing disability determination, or are involved in litigation related to fibromyalgia
10. Any impairment, activity or situation that in the judgment of the PI would prevent satisfactory completion of the study protocol
11. Cognitive behavioral therapy in the last 6 months.
12. Non-fluency in English

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Treatment Participation Rate	10 weeks	Rates of treatment attendance in both arms

Secondary Outcome Measures

Name	Time	Method
Fibromyalgia Impact Questionnaire Revised	Weeks 0, 5, 10, and 14	Comparing overall score of the Fibromyalgia Impact Questionnaire - Revised between the two arms over time.
Completion of Evaluation Rates	Weeks 0, 5, 10 and 14	Completion rates of questionnaires and examinations in both arms
Drop out rate	10 and 14 weeks	Drop out rates in both arms at weeks 10 and 14
Nociceptive Reflex Testing	Weeks 0, 5, 10 and 14	Nociceptive Reflex will be tested at weeks 0, 5, 10 and 14. Changes in nociceptive reflex will be compared within individuals and between arms.
Sleep Quality and Daily Activity	Weeks 0, 5, 10, and 14	Sleep quality and daily activity will be measured using Actiwatch. Changes will be explored within individuals and between groups.

Trial Locations

Locations (1)

Oregon Health & Science University; 🇺🇸 Portland, Oregon, United States